Brain insulin resistance serves as the current thematic focus, reinforcing emerging metabolic-neurologic intersections ...
Neurologists Robert Bermel, MD; Rebecca Cebull, CNP; and Marisa McGinley, DO, discuss where serum neurofilament light and GFAP fit into MS care today and why the field is still waiting on a biomarker ...
Welcome to NeurologyLive® 's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive 's widespread coverage in ...
Overall, fluctuating symptom control was the most commonly cited reason for discontinuing a prior therapy, identified by 57% of providers, while preference for a consistent treatment schedule was the ...
The FDA was busy in September 2026, issuing a number of decisions on potential new therapies, including approvals, clearances ...
Former NASCAR driver Darrell Waltrip recently announced a diagnosis of frontotemporal dementia (FTD). Waltrip, a 3-time ...
Newly announced Phase 4 THRIVE trial results showed most patients who previously had an inadequate response to a ...
Neurology moves fast, and the assumptions that shape how we practice do not always keep up. Gray Areas is a NeurologyLive ...
With two on-label agents now available, the panel turns to what actually drives the choice between them, noting how recently ...
Cerebral palsy (CP) is the most common motor disability of childhood, a group of permanent movement disorders caused by a ...
On September 17, 2026, NeurologyLive convened a clinical forum in Philadelphia titled "Recognizing and Treating Plexiform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results